Black Rock Inc. Tricida, Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.14 - $12.49 $152,786 - $13.6 Million	-1,091,332 Reduced 29.51%	2,607,068 $391,000
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $8.59 Million - $13.7 Million	1,009,907 Added 37.56%	3,698,400 $38.8 Million
Q2 2022 Aug 12, 2022	BUY	$7.31 - $11.85 $12.6 Million - $20.4 Million	1,722,750 Added 178.39%	2,688,493 $26 Million
Q1 2022 May 12, 2022	BUY	$7.35 - $10.63 $36,500 - $52,788	4,966 Added 0.52%	965,743 $7.94 Million
Q4 2021 Feb 10, 2022	BUY	$4.19 - $9.56 $46,798 - $106,775	11,169 Added 1.18%	960,777 $9.19 Million
Q3 2021 Nov 09, 2021	SELL	$3.56 - $4.64 $244,390 - $318,531	-68,649 Reduced 6.74%	949,608 $4.41 Million
Q2 2021 Aug 11, 2021	BUY	$3.95 - $5.41 $4.02 Million - $5.51 Million	1,018,257 New	1,018,257 $4.4 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.